Wells Fargo & Company Boosts uniQure (NASDAQ:QURE) Price Target to $65.00

Key Points

• Wells Fargo & Company raised its price target for uniQure (NASDAQ:QURE) from $30.00 to $65.00, indicating a potential upside of nearly 30% based on the stock's previous close.
• Multiple analysts have recently upgraded uniQure's stock, with the company receiving a consensus rating of "Buy" and an average target price of $58.64.
• uniQure's stock saw a significant increase on Thursday, rising 5.3% to $50.02, while the company reported better-than-expected earnings results, exceeding analysts' estimates.

uniQure (NASDAQ:QURE - Get Free Report) had its price objective lifted by investment analysts at Wells Fargo & Company from $30.00 to $65.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the biotechnology company's stock. Wells Fargo & Company's price objective would suggest a potential upside of 29.95% from the company's previous close.

QURE has been the topic of a number of other reports. Mizuho upgraded shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target on the stock in a research note on Thursday, August 14th. Guggenheim raised their price target on uniQure from $28.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. Stifel Nicolaus boosted their price objective on uniQure from $30.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of uniQure in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $58.64.

uniQure Stock Up 5.3%

Shares of QURE stock traded up $2.52 on Thursday, hitting $50.02. The stock had a trading volume of 5,532,913 shares, compared to its average volume of 1,759,640. uniQure has a 12-month low of $4.45 and a 12-month high of $54.98. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -12.77 and a beta of 0.14. The business has a 50 day moving average of $15.90 and a 200 day moving average of $14.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. As a group, analysts expect that uniQure will post -3.75 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently bought and sold shares of the stock. Vestal Point Capital LP lifted its position in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after acquiring an additional 1,767,572 shares during the period. Nantahala Capital Management LLC boosted its holdings in uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after acquiring an additional 101,598 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock valued at $38,345,000 after acquiring an additional 535,163 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in uniQure in the 2nd quarter worth about $29,217,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after buying an additional 1,491,486 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.